Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma), drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Angiosarcoma outside the UV-exposed skin remains chemoresistant: immunotherapy combinations and antiangiogenic agents are being tested.
EHE: which patients will progress, and TEAD inhibitors as the first fusion-directed therapy.
Radiation-associated breast angiosarcoma incidence after breast-conserving therapy: hyperfractionated re-irradiation and surgery are being studied.
Paediatric vascular tumours are so rare that the evidence base is largely case series; registries are the response.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Active surveillance if asymptomatic and stable; sirolimus for progressive or symptomatic disease; surgery or liver transplant for isolated hepatic disease.
Surveillance first, sirolimus for progression (ESMO Open).
Week-48 progression-free survival 50 percent with paclitaxel against 20 percent with oral etoposide, and 64 percent against 44 percent with bleomycin plus vincristine; both investigational arms were inferior and closed early.
Neuroendocrine cohort: about one in four responded, concentrated in high-grade disease; angiosarcoma cohort about one in four, mostly cutaneous scalp and face tumours; many other cohorts inactive.
Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility.